Raynaud’s is not inherently an autoimmune disease, but it can be closely tied to one. The answer depends on which type you have. Primary Raynaud’s, which accounts for the large majority of cases, has no known autoimmune cause. Secondary Raynaud’s, the less common but more serious form, develops alongside another condition, most often an autoimmune disease like scleroderma or lupus.
Two Types With Very Different Causes
Raynaud’s affects 3 to 5 percent of adults worldwide, making it a fairly common condition. Most of those people have primary Raynaud’s (sometimes called Raynaud’s disease), which tends to appear before age 30, often during the teenage years, and is more common in women. It has no identifiable underlying cause. The blood vessels in your fingers or toes simply overreact to cold or stress, temporarily cutting off blood flow and turning the skin white or blue.
Secondary Raynaud’s (sometimes called Raynaud’s phenomenon) is a different situation. It develops because of damage to blood vessels caused by another disease, and that disease is frequently autoimmune. Scleroderma and lupus are the two most commonly linked conditions, though other connective tissue diseases can also be responsible. Symptoms of secondary Raynaud’s typically appear later in life, around age 40, and the episodes tend to be more severe because the blood vessels themselves are structurally damaged, not just overly reactive.
What Happens Inside Your Blood Vessels
In primary Raynaud’s, the problem is an exaggerated nervous system response. When you’re exposed to cold, your sympathetic nervous system releases chemicals that tell the small arteries in your fingers and toes to constrict. Everyone’s body does this to conserve heat, but in primary Raynaud’s, the receptors on those tiny arteries are abnormally sensitive. They clamp down too hard and too long, temporarily starving the tissue of blood flow. Once you warm up or the stress passes, the vessels relax and blood returns, often with a flush of red and a tingling sensation.
In secondary Raynaud’s, the mechanism is different. The underlying autoimmune disease damages the inner lining of the blood vessels. In scleroderma, for example, scar tissue builds up inside the vessel walls, making them stiff and narrow. The damaged lining also releases a compound called endothelin-1, which triggers further constriction. This combination of structural damage and chemical signaling means the blood flow problems are worse, last longer, and can lead to tissue injury like sores on the fingertips (digital ulcers).
How Doctors Tell the Two Types Apart
If you’ve been diagnosed with Raynaud’s or suspect you have it, the key question your doctor will try to answer is whether an autoimmune condition is driving it. The single most useful tool for this is nailfold capillaroscopy, a painless exam where a doctor looks at the tiny blood vessels at the base of your fingernails under magnification. In primary Raynaud’s, those capillaries look normal and evenly spaced. In secondary Raynaud’s, they often show characteristic abnormalities: enlarged loops, missing vessels, or irregular patterns that signal connective tissue disease, sometimes before other symptoms appear.
An abnormal nailfold capillary pattern is the strongest early predictor that Raynaud’s will turn out to be secondary, with a positive predictive value of 47% in one large meta-analysis. Blood tests for antinuclear antibodies (ANA), which are markers of autoimmune activity, are also commonly ordered. However, a positive ANA alone is not very reliable in this context. Its positive predictive value for an underlying autoimmune disease in Raynaud’s patients is only about 30%, meaning most people who test positive will not go on to develop a secondary condition. Doctors typically use both tests together, along with your age, symptom pattern, and physical exam, to build the full picture.
Signs That Point Toward an Autoimmune Connection
Certain features make it more likely that your Raynaud’s is autoimmune-related rather than primary. Onset after age 40 is one of the clearest signals, since primary Raynaud’s almost always starts earlier. Severe episodes that cause actual tissue damage, such as sores or ulcers on the fingertips, point strongly toward secondary Raynaud’s. Asymmetric symptoms (affecting one hand much more than the other) are also more concerning than the symmetric pattern typical of the primary form.
If you already have joint pain, skin changes, dry eyes and mouth, or unexplained fatigue alongside your Raynaud’s, those symptoms together raise the likelihood of an underlying autoimmune condition. In some cases, Raynaud’s is the very first symptom of a disease like scleroderma, appearing months or even years before other signs develop.
Managing Raynaud’s Day to Day
Regardless of the type, the first line of defense is the same: keep your whole body warm (not just your hands), manage stress, avoid smoking, and stay away from medications that constrict blood vessels, such as certain nasal decongestants. Vibrating tools and equipment can also trigger or worsen symptoms and are worth avoiding.
When lifestyle measures aren’t enough, medications that relax blood vessel walls are the standard next step. These drugs work by preventing calcium from entering the muscle cells around your arteries, which keeps the vessels from clamping down as aggressively. A Cochrane review of the evidence found that these medications reduce attacks by roughly 1 to 2 fewer episodes per week compared to placebo in primary Raynaud’s. That’s a modest but real benefit. The effect on how severe each attack feels, however, appears to be minimal. Side effects like headaches, low blood pressure, and ankle swelling are common enough that some people can’t tolerate them.
For secondary Raynaud’s, treatment is more aggressive because the stakes are higher. If attacks are causing tissue damage or digital ulcers, doctors may use medications that block endothelin-1 (the vessel-constricting compound released by damaged blood vessel walls) or drugs that boost blood flow through other pathways. In severe cases, options include injections that temporarily paralyze the nerves controlling blood vessel constriction, or surgery to cut those nerves permanently, though the long-term results of surgery are uncertain.
For people whose secondary Raynaud’s is driven by an autoimmune disease, treating the underlying condition itself is essential. Getting scleroderma, lupus, or another connective tissue disease under better control can reduce the frequency and severity of Raynaud’s episodes by addressing the root cause of the vascular damage.